CanaQuest Medical Corp. (CANQF)
| Market Cap | 402.53K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -853.85K |
| Shares Out | 21.41M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,000 |
| Average Volume | 1 |
| Open | 0.0140 |
| Previous Close | 0.0188 |
| Day's Range | 0.0140 - 0.0188 |
| 52-Week Range | 0.0102 - 0.1400 |
| Beta | 0.90 |
| RSI | 42.27 |
| Earnings Date | n/a |
About CanaQuest Medical
CanaQuest Medical Corp. develops health products and pharmaceuticals that utilize hemps, cannabis, and algae oils. The company was formerly known as Algae Dynamics Corp. and changed its name to CanaQuest Medical Corp. in January 2019. CanaQuest Medical Corp. was founded in 2008 and is based in Mississauga, Canada. [Read more]
Full Company ProfileNews
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
TORONTO, ON / ACCESSWIRE / July 26, 2023 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest "), a clinical-stage life sciences company focused on drug discovery and development of ...
CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine(R)
TORONTO, ON / ACCESSWIRE / April 25, 2023 / CANAQUEST MEDICAL CORP. (OTC PINK:CANQF) (the "Company" or "CanaQuest "), a clinical-stage life sciences company focused on drug discovery and development o...
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD
Drug Candidate, CQ-001 (cannabidiol "CBD" + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD. TORONTO, ON / ACCESSWIRE / December ...
Canaquest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via WWW.CANAQUESTSTORE.COM, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
USERS REPORT INCREASED MENTAL CLARITY, BETTER SLEEP, MORE ENERGY, AND LESS BRAIN FOG AND JOINT STIFFNESS TORONTO, ON / ACCESSWIRE / September 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Co...
CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health
TORONTO, ON / ACCESSWIRE / April 29, 2021 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing formulations combini...
CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications
TORONTO, ON / ACCESSWIRE / April 7, 2021 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing health and wellness p...
CanaQuest Medical Corp Honored With International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma
TORONTO, ON / ACCESSWIRE / March 29, 2021 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a Life Science/Pharmaceutical Company developing health products utilizing cannabino...